1332837-31-6
Chemical Structure
Fosifloxuridine nafalbenamide
Synonym(s): NUC-3373
- CAS No.: 1332837-31-6
- Formula:C29H29FN3O9P
- Molecular Weight:613.53
IUPAC Name: benzyl ((((2R,3S,5R)-5-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphoryl)-L-alaninate
InChIKey: BIOWRMNRHMERIO-ZVAHOJSLSA-N
SMILES: O=P(OC[C@H]1O[C@@H](N(C=C(F)C2=O)C(N2)=O)C[C@@H]1O)(N[C@@H](C)C(OCC3=CC=CC=C3)=O)OC4=CC=CC5=C4C=CC=C5
Biological Activity: Fosifloxuridine nafalbenamide (NUC-3373), a pyrimidine nucleotide analogue, is a Thymidylate synthase inhibitor. Fosifloxuridine nafalbenamide has anticancer activity. Fosifloxuridine nafalbenamide has the potential to evoke a host immune response and enhance immunoresearch[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Fosifloxuridine nafalbenamide | 96.31% | Fosifloxuridine nafalbenamide (NUC-3373), a pyrimidine nucleotide analogue, is a Thymidylate synthase inhibitor. Fosifloxuridine nafalbenamide has anticancer activity. Fosifloxuridine nafalbenamide has the potential to evoke a host immune response and enhance immunoresearch. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fosifloxuridine nafalbenamide (Standard) | ≥98% | Fosifloxuridine nafalbenamide (Standard) is the analytical standard of Fosifloxuridine nafalbenamide (HY-109115). This product is intended for research and analytical applications. Fosifloxuridine nafalbenamide (NUC-3373), a pyrimidine nucleotide analogue, is a Thymidylate synthase inhibitor. Fosifloxuridine nafalbenamide has anticancer activity. Fosifloxuridine nafalbenamide has the potential to evoke a host immune response and enhance immunoresearch. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Fiona G. McKissock, et al. Abstract 1848: NUC-3373 induces ER stress and the release of damage associated molecular patterns in colorectal cancer cells. Cancer Res August 15 2020 (80) (16 Supplement) 1848.
- [2]. Essam A. Ghazaly, et al. Abstract B46: NUC-3373: A novel pyrimidine nucleotide analogue that overcomes key cancer drug resistance limiting patient survival. Mol Cancer Ther December 1 2015 (14) (12 Supplement 2) B46.
